NO20004545L - FremgangsmÕte for fremstilling av (R)-<alfa>-(2,3- dimetoksyfenyl)-1-[2-(4-fluorofenyl)etyl]-4-piperidinmetanol - Google Patents

FremgangsmÕte for fremstilling av (R)-<alfa>-(2,3- dimetoksyfenyl)-1-[2-(4-fluorofenyl)etyl]-4-piperidinmetanol

Info

Publication number: NO20004545L
Authority: NO; Norway
Prior art keywords: piperidinemethanol; dimethoxyphenyl; fluorophenyl; alpha; ethyl
Prior art date: 1998-03-13

Application number

NO20004545A

Other languages

English (en)

Other versions

NO20004545D0 (no

NO317981B1 (no

Inventor

Alan G Bina

Edward D Daugs

Jonathan Charles Evans

Hans-Wolfram Flemming

Gerard Guillamot

Robert A Hawthorne

Thomas H E Hilpert

James E Hitt

Chi-Hsin R King

Johannes N Koek

Frederick M Laskovics

John Robert Lefler

Alexey Leonid Margolin

Sharon Kay Minish

Thomas T Ortyl

Lian G Rajewski

Marvin J Sack

Paul F Skultety

Sandra Kaye Stolz-Dunn

Alonzo L Tigner

Ian A Tomlinson

Original Assignee

Aventis Pharma Inc

Hoechst Marion Roussel De Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-13

Filing date

2000-09-12

Publication date

2000-11-13

2000-09-12 Application filed by Aventis Pharma Inc, Hoechst Marion Roussel De Gmbh filed Critical Aventis Pharma Inc

2000-09-12 Publication of NO20004545D0 publication Critical patent/NO20004545D0/no

2000-11-13 Publication of NO20004545L publication Critical patent/NO20004545L/no

2005-01-17 Publication of NO317981B1 publication Critical patent/NO317981B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Otolaryngology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Nutrition Science (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Hydrogenated Pyridines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Medicinal Preparation (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO20004545A 1998-03-13 2000-09-12 Fremgangsmate for fremstilling av (R)-<alfa>-(2,3-dimetoksyfenyl)-1-[2-(4-fluorofenyl)etyl]-4-piperidinmetanol, mellomprodukter for bruk ved fremstilling av denne forbindelse og fremgangsmpter for fremstilling av noen av disse mellomprodukter NO317981B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US4225198A	1998-03-13	1998-03-13
US25071899A	1999-02-16	1999-02-16
PCT/US1999/005332 WO1999046245A2 (en)	1998-03-13	1999-03-11	PROCESSES FOR THE PREPARATION OF (R)-α- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL

Publications (3)

Publication Number	Publication Date
NO20004545D0 NO20004545D0 (no)	2000-09-12
NO20004545L true NO20004545L (no)	2000-11-13
NO317981B1 NO317981B1 (no)	2005-01-17

Family

ID=26719032

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20004545A NO317981B1 (no)	1998-03-13	2000-09-12	Fremgangsmate for fremstilling av (R)-<alfa>-(2,3-dimetoksyfenyl)-1-[2-(4-fluorofenyl)etyl]-4-piperidinmetanol, mellomprodukter for bruk ved fremstilling av denne forbindelse og fremgangsmpter for fremstilling av noen av disse mellomprodukter

Country Status (25)

Country	Link
EP (3)	EP1736469A3 (no)
JP (2)	JP4511723B2 (no)
KR (7)	KR100586328B1 (no)
CN (1)	CN100436415C (no)
AR (1)	AR015540A1 (no)
AT (1)	ATE373639T1 (no)
AU (1)	AU755436B2 (no)
BR (1)	BR9909260A (no)
CA (1)	CA2322501C (no)
CY (1)	CY1107104T1 (no)
DE (1)	DE69937162T2 (no)
DK (1)	DK1192134T3 (no)
DZ (1)	DZ2742A1 (no)
EG (1)	EG24052A (no)
ES (1)	ES2294838T3 (no)
HK (1)	HK1042484B (no)
HU (1)	HUP0400889A3 (no)
IL (3)	IL138307A0 (no)
MA (1)	MA25515A1 (no)
NO (1)	NO317981B1 (no)
NZ (1)	NZ506807A (no)
PT (1)	PT1192134E (no)
TN (1)	TNSN99035A1 (no)
TW (1)	TWI249526B (no)
WO (1)	WO1999046245A2 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6713627B2 (en) *	1998-03-13	2004-03-30	Aventis Pharmaceuticals Inc.	Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
DE19934432A1 (de)	1999-07-22	2001-02-01	Merck Patent Gmbh	Indolderivate
EP1370244A1 (en) *	2001-03-12	2003-12-17	Novo Nordisk A/S	Novel tablets and capsules and a process for its preparation
DE102004010132A1 (de)	2004-02-27	2005-09-15	Merck Patent Gmbh	Piperidinderivate
KR101442862B1 (ko) *	2006-12-07	2014-09-22	다이이찌 산쿄 가부시키가이샤	만니톨 또는 유당을 함유하는 고형 제제
US8964338B2 (en)	2012-01-11	2015-02-24	Emerson Climate Technologies, Inc.	System and method for compressor motor protection
CA2904734C (en)	2013-03-15	2018-01-02	Emerson Electric Co.	Hvac system remote monitoring and diagnosis
CN112358398A (zh) *	2020-11-19	2021-02-12	山东新华制药股份有限公司	D-(+)-二对甲苯甲酰酒石酸的回收制备方法
CN116082705B (zh) *	2022-12-05	2023-09-12	苏州易昇光学材料股份有限公司	一种抗黄变自修复凝胶

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4260623A (en) *	1979-11-26	1981-04-07	Warner-Lambert Company	Hexahydro-1-arylspiro(3H-oxazolo(3,4-A)pyridine-3,4'-piperidene) antidepressants, pharmaceutical compositions thereof and method of use thereof
ZA864772B (en) *	1985-07-02	1987-02-25	Merrell Dow Pharma	Novel chemical compounds
US5169096A (en) *	1985-07-02	1992-12-08	Merrell Dow Pharmaceuticals Inc.	N-aralkyl-piperidine-methanol derivatives
JP2869512B2 (ja) *	1990-06-01	1999-03-10	メレルダウファーマスーティカルズインコーポレイテッド	（＋）―α―（２，３―ジメトキシフェニル）―１―［２―（４―フルオロフェニル）エチル］―４―ピペリジンメタノール
ES2096651T3 (es) *	1990-06-07	1997-03-16	Merrell Pharma Inc	Derivados de 1-piperidinil alcanoilarilsulfonamida.
US5477029A (en) *	1994-01-28	1995-12-19	Skutt Ceramic Products, Inc.	Kiln with hinged control panel
US5618824A (en) *	1994-03-09	1997-04-08	Merrell Pharmaceuticals Inc.	Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
EP0796619A1 (en) *	1996-03-21	1997-09-24	Merrell Pharmaceuticals Inc.	Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders

1999
- 1999-03-09 TW TW088103619A patent/TWI249526B/zh not_active IP Right Cessation
- 1999-03-10 MA MA25491A patent/MA25515A1/fr unknown
- 1999-03-10 DZ DZ990043A patent/DZ2742A1/xx active
- 1999-03-10 EG EG23399A patent/EG24052A/xx active
- 1999-03-11 WO PCT/US1999/005332 patent/WO1999046245A2/en not_active Ceased
- 1999-03-11 KR KR1020057024570A patent/KR100586328B1/ko not_active Expired - Fee Related
- 1999-03-11 PT PT99911318T patent/PT1192134E/pt unknown
- 1999-03-11 AU AU29988/99A patent/AU755436B2/en not_active Ceased
- 1999-03-11 AT AT99911318T patent/ATE373639T1/de not_active IP Right Cessation
- 1999-03-11 HU HU0400889A patent/HUP0400889A3/hu unknown
- 1999-03-11 KR KR1020057024569A patent/KR100586327B1/ko not_active Expired - Fee Related
- 1999-03-11 CN CNB998060224A patent/CN100436415C/zh not_active Expired - Fee Related
- 1999-03-11 KR KR1020007010103A patent/KR100591642B1/ko not_active Expired - Fee Related
- 1999-03-11 KR KR1020057024567A patent/KR100591643B1/ko not_active Expired - Fee Related
- 1999-03-11 KR KR1020057024573A patent/KR100591641B1/ko not_active Expired - Fee Related
- 1999-03-11 KR KR1020057024568A patent/KR100591640B1/ko not_active Expired - Fee Related
- 1999-03-11 HK HK02103493.4A patent/HK1042484B/en not_active IP Right Cessation
- 1999-03-11 EP EP06016487A patent/EP1736469A3/en not_active Withdrawn
- 1999-03-11 DK DK99911318T patent/DK1192134T3/da active
- 1999-03-11 NZ NZ506807A patent/NZ506807A/xx unknown
- 1999-03-11 JP JP2000535626A patent/JP4511723B2/ja not_active Expired - Fee Related
- 1999-03-11 KR KR1020057024572A patent/KR100591997B1/ko not_active Expired - Fee Related
- 1999-03-11 ES ES99911318T patent/ES2294838T3/es not_active Expired - Lifetime
- 1999-03-11 TN TNTNSN99035A patent/TNSN99035A1/fr unknown
- 1999-03-11 EP EP06016486A patent/EP1734037A3/en not_active Ceased
- 1999-03-11 EP EP99911318A patent/EP1192134B1/en not_active Expired - Lifetime
- 1999-03-11 AR ARP990101039A patent/AR015540A1/es unknown
- 1999-03-11 CA CA002322501A patent/CA2322501C/en not_active Expired - Fee Related
- 1999-03-11 DE DE69937162T patent/DE69937162T2/de not_active Expired - Lifetime
- 1999-03-11 BR BR9909260-3A patent/BR9909260A/pt not_active Application Discontinuation
- 1999-03-11 IL IL13830799A patent/IL138307A0/xx active IP Right Grant
2000
- 2000-09-06 IL IL138307A patent/IL138307A/en not_active IP Right Cessation
- 2000-09-12 NO NO20004545A patent/NO317981B1/no not_active IP Right Cessation
2006
- 2006-05-29 IL IL175983A patent/IL175983A0/en unknown
2007
- 2007-12-19 CY CY20071101617T patent/CY1107104T1/el unknown
2009
- 2009-12-28 JP JP2009296809A patent/JP2010143925A/ja not_active Abandoned

Also Published As

Publication number	Publication date
WO1999046245A3 (en)	1999-10-21
AU755436B2 (en)	2002-12-12
HUP0400889A2 (hu)	2004-08-30
CA2322501C (en)	2006-05-09
JP2002506059A (ja)	2002-02-26
EP1734037A2 (en)	2006-12-20
KR20060002039A (ko)	2006-01-06
KR20060002036A (ko)	2006-01-06
IL138307A0 (en)	2001-10-31
PT1192134E (pt)	2007-11-13
ES2294838T3 (es)	2008-04-01
KR20060002038A (ko)	2006-01-06
KR20060002034A (ko)	2006-01-06
KR100586328B1 (ko)	2006-06-08
KR100591641B1 (ko)	2006-06-20
DK1192134T3 (da)	2007-11-26
KR20010041819A (ko)	2001-05-25
HK1042484B (en)	2008-05-02
MA25515A1 (fr)	2002-10-01
IL175983A0 (en)	2006-10-05
JP2010143925A (ja)	2010-07-01
BR9909260A (pt)	2000-11-21
EP1736469A2 (en)	2006-12-27
ATE373639T1 (de)	2007-10-15
EP1734037A3 (en)	2010-06-16
TWI249526B (en)	2006-02-21
JP4511723B2 (ja)	2010-07-28
HK1042484A1 (en)	2002-08-16
AU2998899A (en)	1999-09-27
CN100436415C (zh)	2008-11-26
NZ506807A (en)	2003-03-28
TNSN99035A1 (fr)	2005-11-10
HUP0400889A3 (en)	2010-08-30
DZ2742A1 (fr)	2003-09-08
EP1192134A2 (en)	2002-04-03
EP1736469A3 (en)	2010-06-09
DE69937162T2 (de)	2008-06-12
CA2322501A1 (en)	1999-09-16
IL138307A (en)	2006-09-05
AR015540A1 (es)	2001-05-02
DE69937162D1 (de)	2007-10-31
KR100591643B1 (ko)	2006-06-20
EP1192134B1 (en)	2007-09-19
EG24052A (en)	2008-04-13
CN1300280A (zh)	2001-06-20
KR20060002037A (ko)	2006-01-06
KR20060002035A (ko)	2006-01-06
WO1999046245A2 (en)	1999-09-16
KR100586327B1 (ko)	2006-06-08
KR100591640B1 (ko)	2006-06-20
KR100591642B1 (ko)	2006-06-20
NO20004545D0 (no)	2000-09-12
CY1107104T1 (el)	2012-01-25
NO317981B1 (no)	2005-01-17
KR100591997B1 (ko)	2006-06-26

Publication	Publication Date	Title
EE9900441A (et)	2000-04-17	Farmatseutiline kompositsioon N-piperidino-3-pürasoolkarboksamiidi derivaadi, tema soolade ja nende solvaatide suu kaudu manustamiseks
IT1289532B1 (it)	1998-10-15	Composti, di cloridrato di paroxetina e procedimenti per la loro preparazione
NO20033184L (no)	1998-09-18	Anvendelse av forbindelsen (+)-<alfa>-(2,3-dimetoksyfenyl)-1- [2-(4-fluorfenyl)etyl]-4-piperidinmetanol
NO20004545L (no)	2000-11-13	FremgangsmÕte for fremstilling av (R)-<alfa>-(2,3- dimetoksyfenyl)-1-[2-(4-fluorofenyl)etyl]-4-piperidinmetanol
HUP0000960A3 (en)	2001-04-28	Spray-dried paroxetine hydrochloride, process for it's preparation,use of the compound and pharmaceutical compositions containing the same
ITMI950098A0 (it)	1995-01-23	Procedimento per la preparazione di composti metallocenici
IT1274571B (it)	1997-07-17	Procedimento per la preparazione di ¬r-(r,r)\|-5-(3-clorofenil)-3- ¬2-(3,4-dimetossifenil)-1-metil-etil\|-ossazolidin-2-one
CA2427573A1 (en)	2002-05-10	Indole derivatives as pde5-inhibitors
PT1017681E (pt)	2004-06-30	Derivados de hidrazono-benzazuleno composicoes farmaceuticas e intermediarios
NO20011805D0 (no)	2001-04-09	Estere av (+)-<alfa>-(3,2-dimetoksyfenyl)-1-((2-(4- fluorfenyl)etyl)-4-piperidinmetanol) og deres anvendelse somprodrugs for 5HT2A-reseptorantagonist MDL 110.907
AU5553200A (en)	2001-01-09	Process for the preparation of paroxetine and structurally related compounds
IL157061A0 (en)	2004-02-08	Process for the preparation of (3-cyano-1h-indol-7-yl) (4-(4-fluorophenethyl) piperazin-1-yl)-methanone and salts thereof
NO20003145D0 (no)	2000-06-16	FremgangsmÕte for fremstilling av paroxetine-hydroklorid
NO20005158D0 (no)	2000-10-13	FremgangsmÕte for fremstilling av R-(+)-6-karboksamido-3-N- metylamino-1,2,3,4-tetrahydrokarbazol
HUP0202145A3 (en)	2003-02-28	The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders
IT1320401B1 (it)	2003-11-26	Procedimento per la fabbricazione di componenti di un'ossatura ecomponenti di ossatura.
ZA991907B (en)	1999-09-13	Novel processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol.
ZA989842B (en)	2000-04-14	Esters of (+)-Ó-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol.
AU6481799A (en)	2000-05-29	Process for the preparation of paroxetine hydrochloride
AU1396400A (en)	2000-06-19	Process for the preparation of paroxetine hydrochloride
ITMI992457A0 (it)	1999-11-25	Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidrois ochinolin-3-carbossiammide
SI1192134T1 (sl)	2008-02-29	Postopki za pripravo (R)-alfa-(2,3-dimetoksifenil)-1-2-(4-fluorofenil) etil)-4-piperidinmetanola
HUP0203476A3 (en)	2003-07-28	Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate, use thereof and pharmaceutical composition containing the same
SI1353906T1 (en)	2005-02-28	Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof
HK1035900A (en)	2001-12-14	Salts of paroxetine

Legal Events

Date	Code	Title	Description
2010-11-01	MM1K	Lapsed by not paying the annual fees